本邦における Genotype1b・C 型慢性肝炎に対する Peginterferon α-2a+Ribavirin 併用療法と Peginterferon α-2b+Ribavirin 併用療法の早期ウイルス学的反応の検討

概要

論文の詳細を見る
We investigated the early virological response (EVR) to peginterferon (Peg-IFN) α-2a plus ribavirin (RBV) and Peg-IFNα-2b plus RBV therapy in 125 Japanese patients infected with hepatitis C virus (HCV) genotype1b. The rate of EVR, defined as HCV-RNA undetectable by COBAS TaqMan HCV test at 12 weeks after the start of treatment, was not significantly different between Peg-IFNα-2a plus RBV therapy and Peg-IFNα-2b plus RBV therapy (50.0% vs. 52.4%). However, the effect of previous interferon therapy did not influence the EVR rate in both groups. Multiple regression analysis showed that only serum albumin concentration (>4.1 g/dL) was a factor to contribute EVR. Further investigation is necessary, to compare the SVR rate, adverse events, and those in extended combination therapy between the two groups.
2009-10-25